Program: Oral and Poster Abstracts
Session: 332. Antithrombotic Therapy: Poster II
OBJECTIVES: In an effort to reduce overall patient morbidity and healthcare costs, we evaluated current Anti-Xa level monitoring practices in children with VTEs at TCH to develop recommendations for standardizing Anti-Xa level monitoring.
METHODS: Using the TCH DVT Registry, we retrospectively identified 107 subjects diagnosed with uncomplicated VTE and treated with enoxaparin. Demographic information, Anti-Xa levels, dose modifications, and outcomes were abstracted using the electronic medical record (Epic®) and analyzed.
RESULTS: 103 patients had therapeutic Anti-Xa levels at the time of hospital discharge. As instructed, 82 (80%) patients returned for follow-up within 9 days of discharge, with only 59 (72%) patients having therapeutic Anti-Xa levels. Of these 59 subjects, only 34 patients returned to clinic for their 1-month follow-up visit, of which 27 (80%) had therapeutic levels requiring no dose adjustments. Of the original 59 subjects, 29 patients returned for their 2-month follow-up, of which 26 (90%) patients continued to have therapeutic levels.
CONCLUSIONS: Initial therapeutic levels immediately post-discharge are critical to ensuring therapeutic dosing throughout the course of therapy. Once confirmed, the majority of subjects continued to have therapeutic levels at their 1-month (80%) and 2-month follow-ups (90%). Given the discomfort of laboratory testing, costs, and time to families, it may be reasonable to decrease the frequency of laboratory monitoring at these monthly visits.
Disclosures: Off Label Use: Enoxaparin for anticoagulation of pediatric patients with venous thromboembolism.
See more of: Antithrombotic Therapy
See more of: Oral and Poster Abstracts
*signifies non-member of ASH